IBDEI0HP ; ; 19-NOV-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,23914,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23914,1,4,0)
 ;;=4^280.0
 ;;^UTILITY(U,$J,358.3,23914,1,5,0)
 ;;=5^Iron Defic Anemia d/t Chronic Blood Loss
 ;;^UTILITY(U,$J,358.3,23914,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,23915,0)
 ;;=281.9^^127^1430^107
 ;;^UTILITY(U,$J,358.3,23915,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23915,1,4,0)
 ;;=4^281.9
 ;;^UTILITY(U,$J,358.3,23915,1,5,0)
 ;;=5^Nutritional Anemia
 ;;^UTILITY(U,$J,358.3,23915,2)
 ;;=^123801
 ;;^UTILITY(U,$J,358.3,23916,0)
 ;;=281.0^^127^1430^123
 ;;^UTILITY(U,$J,358.3,23916,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23916,1,4,0)
 ;;=4^281.0
 ;;^UTILITY(U,$J,358.3,23916,1,5,0)
 ;;=5^Vit B12 Deficiency (Pernicious Anemia)
 ;;^UTILITY(U,$J,358.3,23916,2)
 ;;=^7161
 ;;^UTILITY(U,$J,358.3,23917,0)
 ;;=282.60^^127^1430^111
 ;;^UTILITY(U,$J,358.3,23917,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23917,1,4,0)
 ;;=4^282.60
 ;;^UTILITY(U,$J,358.3,23917,1,5,0)
 ;;=5^Sickle-Cell Anemia
 ;;^UTILITY(U,$J,358.3,23917,2)
 ;;=^7188
 ;;^UTILITY(U,$J,358.3,23918,0)
 ;;=282.62^^127^1430^112
 ;;^UTILITY(U,$J,358.3,23918,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23918,1,4,0)
 ;;=4^282.62
 ;;^UTILITY(U,$J,358.3,23918,1,5,0)
 ;;=5^Sickle-Cell With Crisis
 ;;^UTILITY(U,$J,358.3,23918,2)
 ;;=^267982
 ;;^UTILITY(U,$J,358.3,23919,0)
 ;;=281.1^^127^1430^124
 ;;^UTILITY(U,$J,358.3,23919,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23919,1,4,0)
 ;;=4^281.1
 ;;^UTILITY(U,$J,358.3,23919,1,5,0)
 ;;=5^Vit B12 Deficiency(Dietary)
 ;;^UTILITY(U,$J,358.3,23919,2)
 ;;=^267974
 ;;^UTILITY(U,$J,358.3,23920,0)
 ;;=286.7^^127^1430^54
 ;;^UTILITY(U,$J,358.3,23920,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23920,1,4,0)
 ;;=4^286.7
 ;;^UTILITY(U,$J,358.3,23920,1,5,0)
 ;;=5^Coagulation Defect(Any),Acquired
 ;;^UTILITY(U,$J,358.3,23920,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,23921,0)
 ;;=289.9^^127^1430^120
 ;;^UTILITY(U,$J,358.3,23921,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23921,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,23921,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,23921,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,23922,0)
 ;;=451.9^^127^1430^121
 ;;^UTILITY(U,$J,358.3,23922,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23922,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,23922,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,23922,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,23923,0)
 ;;=446.6^^127^1430^122
 ;;^UTILITY(U,$J,358.3,23923,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23923,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,23923,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(Ttp)
 ;;^UTILITY(U,$J,358.3,23923,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,23924,0)
 ;;=286.4^^127^1430^125
 ;;^UTILITY(U,$J,358.3,23924,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23924,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,23924,1,5,0)
 ;;=5^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,23924,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,23925,0)
 ;;=204.00^^127^1430^1
 ;;^UTILITY(U,$J,358.3,23925,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23925,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,23925,1,5,0)
 ;;=5^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,23925,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,23926,0)
 ;;=204.01^^127^1430^3
 ;;^UTILITY(U,$J,358.3,23926,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23926,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,23926,1,5,0)
 ;;=5^ALL,In Remission
 ;;^UTILITY(U,$J,358.3,23926,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,23927,0)
 ;;=204.10^^127^1430^16
 ;;^UTILITY(U,$J,358.3,23927,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23927,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,23927,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,23927,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,23928,0)
 ;;=204.11^^127^1430^18
 ;;^UTILITY(U,$J,358.3,23928,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23928,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,23928,1,5,0)
 ;;=5^CLL,In Remission
 ;;^UTILITY(U,$J,358.3,23928,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,23929,0)
 ;;=201.90^^127^1430^83
 ;;^UTILITY(U,$J,358.3,23929,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23929,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,23929,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,23929,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,23930,0)
 ;;=785.6^^127^1430^89
 ;;^UTILITY(U,$J,358.3,23930,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23930,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,23930,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,23930,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,23931,0)
 ;;=200.20^^127^1430^90
 ;;^UTILITY(U,$J,358.3,23931,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23931,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,23931,1,5,0)
 ;;=5^Lymphoma,Burkitt's,Site Unspec
 ;;^UTILITY(U,$J,358.3,23931,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,23932,0)
 ;;=202.00^^127^1430^92
 ;;^UTILITY(U,$J,358.3,23932,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23932,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,23932,1,5,0)
 ;;=5^Lymphoma,Low-Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,23932,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,23933,0)
 ;;=200.10^^127^1430^91
 ;;^UTILITY(U,$J,358.3,23933,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23933,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,23933,1,5,0)
 ;;=5^Lymphoma,Int or High Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,23933,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,23934,0)
 ;;=273.3^^127^1430^93
 ;;^UTILITY(U,$J,358.3,23934,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23934,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,23934,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,23934,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,23935,0)
 ;;=203.00^^127^1430^103
 ;;^UTILITY(U,$J,358.3,23935,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23935,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,23935,1,5,0)
 ;;=5^Multiple Myeloma w/o Remission
 ;;^UTILITY(U,$J,358.3,23935,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,23936,0)
 ;;=203.01^^127^1430^105
 ;;^UTILITY(U,$J,358.3,23936,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23936,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,23936,1,5,0)
 ;;=5^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,23936,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,23937,0)
 ;;=238.6^^127^1430^108
 ;;^UTILITY(U,$J,358.3,23937,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23937,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,23937,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,23937,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,23938,0)
 ;;=205.00^^127^1430^4
 ;;^UTILITY(U,$J,358.3,23938,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23938,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,23938,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,23938,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,23939,0)
 ;;=205.01^^127^1430^6
 ;;^UTILITY(U,$J,358.3,23939,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23939,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,23939,1,5,0)
 ;;=5^AML,In Remission
 ;;^UTILITY(U,$J,358.3,23939,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,23940,0)
 ;;=205.10^^127^1430^19
 ;;^UTILITY(U,$J,358.3,23940,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23940,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,23940,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,23940,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,23941,0)
 ;;=205.11^^127^1430^21
 ;;^UTILITY(U,$J,358.3,23941,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23941,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,23941,1,5,0)
 ;;=5^CML,In Remission
 ;;^UTILITY(U,$J,358.3,23941,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,23942,0)
 ;;=289.0^^127^1430^55
 ;;^UTILITY(U,$J,358.3,23942,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23942,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,23942,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,23942,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,23943,0)
 ;;=238.4^^127^1430^109
 ;;^UTILITY(U,$J,358.3,23943,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23943,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,23943,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,23943,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,23944,0)
 ;;=V58.61^^127^1430^126
 ;;^UTILITY(U,$J,358.3,23944,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23944,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,23944,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,23944,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,23945,0)
 ;;=282.49^^127^1430^117
 ;;^UTILITY(U,$J,358.3,23945,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23945,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,23945,1,5,0)
 ;;=5^Thalassemia NEC
 ;;^UTILITY(U,$J,358.3,23945,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,23946,0)
 ;;=289.89^^127^1430^15
 ;;^UTILITY(U,$J,358.3,23946,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23946,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,23946,1,5,0)
 ;;=5^Blood Diseases NEC
 ;;^UTILITY(U,$J,358.3,23946,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,23947,0)
 ;;=238.79^^127^1430^88
 ;;^UTILITY(U,$J,358.3,23947,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23947,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,23947,1,5,0)
 ;;=5^Lymph/Hematopoietic Tissue NEC
 ;;^UTILITY(U,$J,358.3,23947,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,23948,0)
 ;;=287.30^^127^1430^110
 ;;^UTILITY(U,$J,358.3,23948,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23948,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,23948,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,23948,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,23949,0)
 ;;=288.09^^127^1430^8
 ;;^UTILITY(U,$J,358.3,23949,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23949,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,23949,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,23949,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,23950,0)
 ;;=V10.21^^127^1430^61
 ;;^UTILITY(U,$J,358.3,23950,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23950,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,23950,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,23950,2)
 ;;=^295214
